Consequences of antibody binding in vitro on the pharmacological properties of anisoylated plasminogen streptokinase activator complex.
Fears
R
R
Beecham Pharmaceuticals Research Division, Great Burgh, Epsom.
Ferres
H
H
Hibbs
M
M
Standring
R
R
D016255:Anistreplase; D000937:Antigen-Antibody Reactions; D005343:Fibrinolytic Agents / Q000097:blood / Q000276:immunology* / Q000494:pharmacology; D006207:Half-Life; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D066298:In Vitro Techniques; D010958:Plasminogen / Q000097:blood / Q000276:immunology* / Q000494:pharmacology; D013300:Streptokinase / Q000097:blood / Q000276:immunology* / Q000494:pharmacology
D005343:Fibrinolytic Agents; D007074:Immunoglobulin G; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase